{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:21:04Z","timestamp":1790342464697,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.actbio.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T12:09:35Z","timestamp":1549973375000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Augmenting the synergies of chemotherapy and immunotherapy through drug delivery"],"prefix":"10.1016","volume":"88","author":[{"given":"Jihoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret P.","family":"Manspeaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan N.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2019.02.012_b0005","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0010","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the Antitumor Agent Smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/micc.12228","article-title":"A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems solutions, and prospects","volume":"23","author":"Maeda","year":"2016","journal-title":"Microcirculation"},{"key":"10.1016\/j.actbio.2019.02.012_b0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18433\/J30C7D","article-title":"Nanotherapeutics to overcome conventional cancer chemotherapy limitations","volume":"14","author":"Moorthi","year":"2011","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.actbio.2019.02.012_b0030","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0035","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2019.02.012_b0040","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0045","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0050","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2019.02.012_b0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2019.02.012_b0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/ctrv.2001.0222","article-title":"Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer","volume":"27","author":"Gomez","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/PPO.0b013e3181eb5066","article-title":"Chemoimmunotherapy","volume":"16","author":"Emens","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.actbio.2019.02.012_b0085","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained Remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0090","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.02.012_b0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.02.012_b0105","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nri1845","article-title":"Dendritic cells in a mature age","volume":"6","author":"Sousa","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun."},{"key":"10.1016\/j.actbio.2019.02.012_b0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.actbio.2019.02.012_b0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.actbio.2019.02.012_b0125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2019.02.012_b0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0145","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0150","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2019.02.012_b0155","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.actbio.2019.02.012_b0160","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0165","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.02.012_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/intimm\/dxu095","article-title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","volume":"27","author":"Philips","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0175","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2019.02.012_b0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","article-title":"Biomaterial-assisted targeted modulation of immune cells in cancer treatment","volume":"17","author":"Wang","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.actbio.2019.02.012_b0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.actbio.2019.02.012_b0205","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.4049\/jimmunol.181.11.7670","article-title":"Targeting Poly I: C to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN\u03b1\/\u03b2","volume":"181","author":"Ngoi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0210","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","article-title":"In-situ tumor vaccination: bringing the fight to the tumor","volume":"11","author":"Pierce","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.actbio.2019.02.012_b0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0220","article-title":"Role of IL-2 in cancer immunotherapy","volume":"25","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.actbio.2019.02.012_b0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0230","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0235","first-page":"cm1","article-title":"Interleukin-1, (IL-1) Pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.actbio.2019.02.012_b0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12079-015-0302-x","article-title":"A network map of Interleukin-10 signaling pathway","volume":"10","author":"Verma","year":"2016","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.actbio.2019.02.012_b0245","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1084\/jem.20042276","article-title":"TGF-\u03b21 maintains suppressor function and Foxp3 expression in CD4 CD25 regulatory T cells","volume":"201","author":"Marie","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.actbio.2019.02.012_b0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2015.12.027","article-title":"Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes","volume":"223","author":"Rohner","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0265","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biomaterials.2013.10.003","article-title":"Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response","volume":"35","author":"Thomas","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2019.02.012_b0270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.addr.2017.04.011","article-title":"Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy","volume":"114","author":"Francis","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri.2017.140","article-title":"The dawn of vaccines for cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0280","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn5062029","article-title":"Nanoparticle-based immunotherapy for cancer","volume":"9","author":"Shao","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2019.02.012_b0285","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.trecan.2015.07.008","article-title":"Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance","volume":"1","author":"Medler","year":"2015","journal-title":"Trends Cancer."},{"key":"10.1016\/j.actbio.2019.02.012_b0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.actbio.2019.02.012_b0300","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0305","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0310","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/bjc.2017.446","article-title":"Immune gene expression and response to chemotherapy in advanced breast cancer","volume":"118","author":"Foukakis","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0315","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.18632\/oncotarget.2266","article-title":"Immunogenic cell death inducers as anticancer agents","volume":"5","author":"Kepp","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.actbio.2019.02.012_b0320","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1158\/0008-5472.CAN-09-1101","article-title":"Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells","volume":"69","author":"Tanaka","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4142\/jvs.2003.4.3.229","article-title":"Altered maturation of dendritic cells by taxol, an anticancer drug","volume":"4","author":"Joo","year":"2003","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.actbio.2019.02.012_b0330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2172-11-14","article-title":"Differential effects of Paclitaxel on dendritic cell function","volume":"11","author":"John","year":"2010","journal-title":"BMC Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0335","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1479-5876-7-58","article-title":"Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentration","volume":"7","author":"Kaneno","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0345","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.intimp.2010.11.021","article-title":"Selective impairment of CD4+CD25+Foxp3+Regulatory T cells by paclitaxel is explained by Bcl-2\/Bax mediated apoptosis","volume":"11","author":"Liu","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.actbio.2019.02.012_b0350","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clim.2008.07.013","article-title":"Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy","volume":"129","author":"Zhang","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0355","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00262-008-0586-2","article-title":"Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse","volume":"58","author":"Vicari","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2019.02.012_b0360","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-3083.2011.02514.x","article-title":"CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of Toll-like receptor 4","volume":"73","author":"Zhu","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/1547691X.2012.655343","article-title":"Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice","volume":"9","author":"Sevko","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.actbio.2019.02.012_b0370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellimm.2010.03.001","article-title":"Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice","volume":"263","author":"Pfannenstiel","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.actbio.2019.02.012_b0375","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1016\/j.vaccine.2010.04.046","article-title":"Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice","volume":"28","author":"Yuana","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2019.02.012_b0380","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.actbio.2019.02.012_b0385","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2019.02.012_b0390","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0395","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao1736","article-title":"Elimination of established tumors with nanodisc-based combination chemoimmunotherapy","volume":"4","author":"Kuai","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.actbio.2019.02.012_b0400","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/bc9004443","article-title":"Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins","volume":"21","author":"van der Vlies","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2019.02.012_b0405","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0410","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.192.10.1425","article-title":"Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex","volume":"192","author":"Gretz","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0415","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1021\/acsbiomaterials.6b00438","article-title":"Flexible macromolecule versus rigid particle retention in the injected skin and accumulation in draining lymph nodes are differentially influenced by hydrodynamic size","volume":"3","author":"Rohner","year":"2017","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.actbio.2019.02.012_b0420","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2019.02.012_b0425","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41551-018-0254-6","article-title":"A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer","volume":"2","author":"Kulkarni","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2019.02.012_b0430","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41551-018-0276-0","article-title":"Instructing macrophages to fight cancer","volume":"2","author":"Gustafson","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2019.02.012_b0435","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2019.02.012_b0440","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0445","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.actbio.2019.02.012_b0450","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/2326-6066.CIR-15-0052","article-title":"Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression","volume":"3","author":"van der Sluis","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0455","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.11.021","article-title":"Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity","volume":"269","author":"Mastria","year":"2018","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0460","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1038\/ncomms8939","article-title":"A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models","volume":"6","author":"Bhattacharyya","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.02.012_b0465","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1021\/acsnano.8b01890","article-title":"Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma","volume":"12","author":"Liu","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2019.02.012_b0470","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.actbio.2019.02.012_b0475","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nnano.2009.314","volume":"5","author":"Choi","year":"2010","journal-title":"Nat. Nanotech."},{"key":"10.1016\/j.actbio.2019.02.012_b0480","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.7150\/thno.19987","article-title":"Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency","volume":"7","author":"Kong","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2019.02.012_b0485","doi-asserted-by":"crossref","first-page":"44402","DOI":"10.1021\/acsami.7b16787","article-title":"Synthesis of pH-responsive biodegradable mesoporous silica-calcium phosphate hybrid nanoparticles as a high potential drug carrier","volume":"9","author":"He","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2019.02.012_b0490","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1039\/C5NR09112H","article-title":"Breakable mesoporous silica nanoparticles for targeted drug delivery","volume":"8","author":"Maggini","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2019.02.012_b0495","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/adhm.201600246","article-title":"Stimuli-regulated enzymatically degradable smart graphene-oxide-polymer nanocarrier facilitating photothermal gene delivery","volume":"5","author":"Kim","year":"2016","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biomaterials.2016.06.015","article-title":"Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging","volume":"102","author":"Cheheltani","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2019.02.012_b0505","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2017.10.024","article-title":"Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment","volume":"268","author":"Li","year":"2017","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0510","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1021\/acsnano.7b08148","article-title":"Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel","volume":"12","author":"Jin","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2019.02.012_b0515","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biomaterials.2016.01.006","article-title":"Combinatorial prospects of nano-targeted chemoimmunotherapy","volume":"83","author":"Da Silva","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2019.02.012_b0520","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1021\/acs.nanolett.7b03186","article-title":"Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy","volume":"17","author":"Song","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2019.02.012_b0525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2017.11.037","article-title":"Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects","volume":"269","author":"Zhao","year":"2018","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0530","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/acs.molpharmaceut.8b00564","article-title":"Co-delivery of doxorubicin and interferon-\u03b3 by thermosensitive nanoparticles for cancer immunochemotherapy","volume":"15","author":"Yin","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2019.02.012_b0535","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jconrel.2018.08.011","article-title":"Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity","volume":"286","author":"Gu","year":"2018","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0540","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1021\/acs.nanolett.7b01193","article-title":"Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy","volume":"17","author":"Shen","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2019.02.012_b0545","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","article-title":"Smart superstructures with ultrahigh ph-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration","volume":"10","author":"Li","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2019.02.012_b0550","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.02.012_b0555","doi-asserted-by":"crossref","first-page":"1803001","DOI":"10.1002\/adma.201803001","article-title":"Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment","volume":"30","author":"Feng","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0560","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1039\/C5BM00039D","article-title":"Polymeric biomaterials for the delivery of platinum-based anticancer drugs","volume":"3","author":"Kim","year":"2015","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.actbio.2019.02.012_b0565","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2017.04.011","article-title":"Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy","volume":"255","author":"Wu","year":"2017","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2019.02.012_b0570","first-page":"118","article-title":"DOX\/IL-2\/IFN-\u03b3 co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment","volume":"3","author":"Lv","year":"2018","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0575","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species\u2013responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy,","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.actbio.2019.02.012_b0580","doi-asserted-by":"crossref","first-page":"1801527","DOI":"10.1002\/adma.201801527","article-title":"Injectable bioresponsive gel depot for enhanced immune checkpoint blockade","volume":"30","author":"Yu","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2019.02.012_b0585","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1038\/ncomms8556","article-title":"Injectable cryogel-based whole-cell cancer vaccines","volume":"6","author":"Bencherif","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.02.012_b0590","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","article-title":"Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody","volume":"16","author":"Wang","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2019.02.012_b0595","doi-asserted-by":"crossref","first-page":"9702","DOI":"10.1021\/acsnano.8b04146","article-title":"Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2019.02.012_b0600","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.progpolymsci.2005.09.004","article-title":"Polymer\u2013drug conjugates: progress in polymeric prodrugs","volume":"31","author":"Khandare","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.actbio.2019.02.012_b0605","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1038\/ncomms4702","article-title":"Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy","volume":"5","author":"Namgung","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.02.012_b0610","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.progpolymsci.2012.07.002","article-title":"Design and development of polymeric micelles with cleavable links for intracellular drug delivery","volume":"38","author":"Wei","year":"2013","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.actbio.2019.02.012_b0615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2019.02.012_b0620","doi-asserted-by":"crossref","first-page":"5","DOI":"10.53879\/id.54.08.11148","article-title":"Lymphatic delivery: concept, challenges and applications","volume":"54","author":"Bora","year":"2017","journal-title":"Indian Drugs"},{"key":"10.1016\/j.actbio.2019.02.012_b0625","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coche.2014.11.003","article-title":"Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery","volume":"7","author":"Thomas","year":"2015","journal-title":"Curr. Opin. Chem. Eng."},{"key":"10.1016\/j.actbio.2019.02.012_b0630","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0145-2126(01)00138-2","article-title":"Chemotherapy-induced immunosuppression and reconstitution of immune function","volume":"26","author":"Steele","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2019.02.012_b0635","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.4-5-370","article-title":"T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review","volume":"4","author":"Mackall","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.actbio.2019.02.012_b0640","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood.V89.10.3700","article-title":"Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy","volume":"89","author":"Mackall","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2019.02.012_b0645","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00262-012-1343-0","article-title":"Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo","volume":"62","author":"Tongu","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2019.02.012_b0650","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2019.02.012_b0655","first-page":"141","article-title":"Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide","volume":"16","author":"Motoyoshi","year":"2006","journal-title":"Oncol. Rep."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119301163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119301163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:19:21Z","timestamp":1761671961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706119301163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":131,"alternative-id":["S1742706119301163"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2019.02.012","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmenting the synergies of chemotherapy and immunotherapy through drug delivery","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}